These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32414711)

  • 41. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 42. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction.
    Amraei R; Rahimi N
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations.
    Hanff TC; Harhay MO; Brown TS; Cohen JB; Mohareb AM
    Clin Infect Dis; 2020 Jul; 71(15):870-874. PubMed ID: 32215613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
    Buckley LF; Cheng JWM; Desai A
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.
    Hrenak J; Simko F
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19, ACE2, and the cardiovascular consequences.
    South AM; Diz DI; Chappell MC
    Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1084-H1090. PubMed ID: 32228252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19.
    Touyz RM; Li H; Delles C
    Clin Sci (Lond); 2020 Apr; 134(7):747-750. PubMed ID: 32255491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 51. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
    de Maat S; de Mast Q; Danser AHJ; van de Veerdonk FL; Maas C
    Semin Thromb Hemost; 2020 Oct; 46(7):835-837. PubMed ID: 32526773
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 54. ACE2, Much More Than Just a Receptor for SARS-COV-2.
    Samavati L; Uhal BD
    Front Cell Infect Microbiol; 2020; 10():317. PubMed ID: 32582574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
    Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
    Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
    Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
    Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
    [No Abstract]   [Full Text] [Related]  

  • 57. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.
    Li Y; Zhou W; Yang L; You R
    Pharmacol Res; 2020 Jul; 157():104833. PubMed ID: 32302706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
    Zhang J; Wang M; Ding W; Wan J
    Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apelin-potential therapy for COVID-19?
    Saeedi Saravi SS; Beer JH
    J Mol Cell Cardiol; 2020 Aug; 145():84-87. PubMed ID: 32562701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19.
    Yang S; Meng G
    J Mol Cell Cardiol; 2020 Apr; 141():110-111. PubMed ID: 32272142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.